Q-omics provides the consensus-scored USP9X profile across patient tissues and cancer cell-line models. USP9X expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP9X is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, USP9X RNA expression shows 21,043 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where USP9X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP9X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP9X survival associations across molecular data types. USP9X RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP9X RNA expression–survival associations across cancer types. High USP9X expression shows unfavorable associations in MESO, CESC, UVM and STAD, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP9X RNA expression.
This table summarizes USP9X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for USP9X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP9X shows lower tumor expression in THCA and higher tumor expression in BRCA, HNSC, LUAD, STAD and LIHC. The THCA box plot shows higher USP9X RNA expression in normal versus tumor tissue (log2 FC = −0.492, t-test p < 0.001).
This table shows molecular features associated with USP9X in patient tissues and cancer cell lines. In patient samples, USP9X shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, USP9X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
